Navigation Links
Strong in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced its financial results for the quarter ended June 30, 2009. During 2009 Isis has continued to successfully execute its business strategy and as a result reported $669...

Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community

Study findings offer hope for increased life expectancy for people with Down syndrome WASHINGTON, Aug. 18 /PRNewswire-USNewswire/ -- In the world of Down syndrome, 'Mr. C' is a rarity. A real person whose progress has been tracked for the past 16 years, at seventy, 'Mr. C' has well surpassed...

Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008

ROCHESTER, N.Y., July 17 /PRNewswire-USNewswire/ -- Strong National Museum of Play is pleased to announce the launch in mid-July of the American Journal of Play, the first interdisciplinary journal anywhere dedicated solely to the study of play. The inaugural issue enters the scholarly scene...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

HOUSTON, June 2 /PRNewswire/ -- Physicians affiliated with the US Oncology Research Network are presenting the results of their clinical research at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 30 - June 3, 2008 in Chicago. Dr. Joyce O'Shaughnessy of T...

SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents

NATICK, Mass. and BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed two-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety and efficacy of the market-leading TAXUS(R) Express2(TM) P...

Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures

NATICK, Mass., and WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed results from the SPIRIT III Clinical Trial, which continue to support the proven safety and efficacy of the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Corona...

AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study

AppyScore(TM), the First Blood-based Screen / Triage Test for Human Appendicitis, Advances in FDA Application Process with Test Results Showing Sensitivity Level of 98%. CASTLE ROCK, Colo., Sept. 28 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY ) an eme...

Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported that a standard panel of safety tests was recently completed with the humanized version of Sphingomab(TM), and the findings indicate...

Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study

Chief Scientist to Present Results at 2007 American Association for Cancer Research Annual Meeting CLEVELAND, April 09, 2007 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. , announced today the results of its study of Protectan CBLB502's efficacy as a mitigator of both gastrointestinal (GI) and...

Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill

First significant drug safety measure in 45 years; focus moves to House WASHINGTON, May 09, 2007 /PRNewswire-USNewswire/ -- The Senate today overwhelmingly passed significant prescription drug safety reforms to give the Food and Drug Administration more power to deal with unsafe medicines on the m...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p - Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels - Detailed results presented today at the Seventeenth European Meeting on Hypertension in Mil...

Regular Yoga Practice Is Associated With Mindful Eating

... when full - weighed less than those who ate mindlessly, who ate when not hungry or in response to anxiety or depression. The researchers also found a strong association between yoga practice and mindful eating but found no association between other types of physical activity, such as walking or running, an...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...osts and expenses were down 28% to $83.5 million as compared to $115.6 million in the first half of 2008. "In the first half of 2009, we made a strong commitment to advancing our clinical pipeline," stated Howard W. Robin, President and Chief Executive Officer of Nektar. "We completed our Phase 2 cl...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

... believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's website: http://www.shire.com . "SAFE HARBOR" STATEMENT UNDER THE...

Diabetes Gene Raises Odds of Lower Birth Weight

...esearchers compared birth weights with the occurrence of the 20 gene variants. They found that one of the gene variants, called CDKAL1 , had a strong association with lower birth weight -- a finding that supports the so-called fetal insulin hypothesis. Previous studies by European diabetes researche...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

... believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's website: http://www.shire.com . "SAFE HARBOR" STATEMENT UNDER THE...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

...ntial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability,...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

...e received picoplatin in clinical studies to date. Additional safety and anticipated efficacy data from our ongoing Phase 3 SPEAR study will provide a strong database to support the NDA filing." The Company plans to present data from the Phase 1 cardiac safety trial at a medical conference later th...

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

...(Scotland) Limited (CT), is located in East Kilbride (near Glasgow). CT develops and manufactures controlled-release drug delivery products and has a strong focus in the area of women's health, including manufacturing the successful cervical ripening product, the Cervidil(R) vaginal insert (Propess(R) in E...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

...our vaccines do not require the use of an adjuvant, and they raise not only strong antibody responses but robust cellular responses, both of which could be im...abase on April 25th. Mice inoculated with the AlphaVax H1N1 vaccine showed strong dose-dependent hemagglutination inhibition ("HI") antibody responses. Afte...

Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity

...tivity of Menerba (MF101) and Liquiritigenin, two of Bionovo's ERb selective drugs, in different cell types. These compelling findings will serve as a strong impetus for Bionovo, Inc. to continue investigating the unique abilities of their drugs to safely and effectively treat menopausal symptoms. ...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

...stine. When reovirus was used alone, it demonstrated significant cytolytic activity in 7 of 9 NSCLC cell lines examined. The combinations demonstrated strong synergistic effects on cell killing. The combination of reovirus and paclitaxel was invariably synergistic in all cell lines tested, regardless of the...

Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease

... believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's website: http://www.shire.com . "SAFE HARBOR" STATEMENT UNDER THE...

PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it

...p your brain healthier as you age. These steps might also reduce your risk of developing Alzheimer's disease or another dementia." "There's a strong and credible association between heart health and brain health. If people learn about and do some simple lifestyle modifications, such as being more p...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...ressure medications were standard doses of common blood pressure medications such as ACE inhibitors or diuretics. "R788 continues to perform with strong efficacy and good tolerability in the groups of patients with RA who have failed to respond to methotrexate," said Elliott Grossbard, M.D., chief medi...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

...s of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eis...

Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy

... Christopher O'Connor, Director Heart Center, Duke University Medical Center commented on the MARVEL program "We believe it is an endeavor worthy of strong support. It is hopeful that MARVEL II, which is one stage of the broader MARVEL program, will meet a key efficacy end point - the six-minute walk." ...

New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation

...normal electrical signals may cause an arrhythmia to start. Different techniques and instruments can be used for the procedure. While there is no strong evidence to suggest that one particular technique is best for any given patient, there is general consensus concerning a basic approach to ablation pr...

Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

... believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's website: http://www.shire.com . "SAFE HARBOR" STATEMENT UNDER THE...

UNT Health Science Center's Groundbreaking Research Applied to Protecting Brain After Traumatic Injury

... that we can protect the brain and increase survival." Simpkins' studies in animals found that rapidly administering a single dose of estrogen, a strong anti-oxidant and an anti-inflammatory drug, following a stroke increases brain cell survival by up to 65 percent. Estrogens delivered intravenously po...

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

...International; these include TB-402 (Anti-Factor VIII), a long acting anticoagulant, and TB-403 (anti-PlGF) for cancer. ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at t...

Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value

...s of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eis...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

...ional Schizophrenia Consortium (ISC) and the European-American portion of the Molecular Genetics of Schizophrenia studies (MGS). Twenty-five SNPs with strong suggestive correlation were then followed up in more than 20,000 patients and controls from the Netherlands, Denmark, Germany, Hungary, Norway, Russia...

Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc.

...m Garlic Research Labs, Inc. is being used successfully by city parks, golf courses and individuals all across the country. Mosquito Barrier is a very strong liquid garlic made from very potent garlic cloves which is considerably more potent than the garlic found in grocery stores. Garlic has a natural sulf...

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

...sectome. In just the first year of operations, Pangu BioPharma has built a strong patent portfolio that provides fundamental components of aTyr Pharma's port...components of aTyr Pharma's product generating engine, and are proof of the strong support Pangu BioPharma receives from the Hong Kong government and HKUST." ...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

...est Portuguese pharmaceutical company and is based in S. Mamede do Coronado, Portugal. It is the partner of choice for many companies, having a strong presence in the Iberian peninsula as well as in over 10 countries in Latin America and in around 20 French or Portuguese speaking African countries. ...

New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%

...ys. Oligofructose enriched inulin is a 100% natural, plant-derived 'compound' prebiotic fiber which has extensive clinical research demonstrating strong health benefits. Plain inulin is a far cheaper prebiotic which is used in most prebiotic supplements and enhanced foods. "The implications of thi...

ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule

...tion in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye. These adhesions can cause ve...oagulant, and TB-403 (anti-PlGF) for cancer. ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechn...

Alfacell Provides Shareholder Update

... regulate the protein produced by the MDR1 gene. There is ample evidence this may be the case, and if so, as previously mentioned, Onconase would be a strong candidate to be used as an adjunct to other chemo therapy regimes. Of course, our ability to continue with these efforts will depend on our abili...

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

...d-2010. "The research published today in Nature Medicine provides a strong rationale for clinical development of PR-957 in rheumatoid arthritis and ot...an oral proteasome inhibitor also targeted in oncology, and now PR-957 as a strong drug candidate for the treatment of autoimmune disorders. This demonstrate...
Other Tags
(Date:7/10/2014)... , July 7, 2014 According ... Research "Electronic Access Control Systems Market Global Forecast, Market ... the global Electronic Access Control systems market was valued ... to grow at a CAGR of 12.6% from 2014 ... 31,187.8 million in 2019. Browse the full ...
(Date:7/10/2014)... , July 9, 2014  Acuity Market Intelligence today released ... 2014 Edition" indicating that the global market for National Electronic ... 2013 to 2018. During this time, the number of National ... 3.5 billion. Asia , with its vast ... National eID cards issued, while Europe ...
(Date:7/10/2014)... belongs to the large, mainly tropical flowering plant family ... in the family rely on bees for their pollination. Only ... or vertebrates. The flowers of Axinaea appear in ... petals of the different species are pink, yellow, orange or ... the contrasting colours of their bulbous appendages. The pollination mechanism ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2Novel type of bird pollination mechanism discovered in South America 2
(Date:7/13/2014)... ability to identify odors might indicate the development ... of the eye could indicate the build-up of ... brain, according to the results of four research ... Conference 2014 (AAIC 2014) in Copenhagen. , In ... identify odors was significantly associated with loss of ...
(Date:7/13/2014)... 13, 2014 ECS is ... “As a parent of a special needs child, I ... the Seattle community for contemporary special education resources and ... alternative to students and families in the Seattle metro ... environment for special education. We welcome the opportunity to ...
(Date:7/13/2014)... 2014 Recently, iFitDress.com, one of the ... occasion outfits, has added a new selection of beautiful ... company has launched a promotion for these evening gowns. ... iFitDress.com is now providing thousands of graceful gowns in ... in Britain, America, France, Italy and many other countries. ...
(Date:7/12/2014)... The Passenger Information System market is estimated to grow ... 2019, at an expected CAGR of 26.5% for the ... infrastructure in North America is well developed and network ... of the region. The growing ridership figures in public ... are driving the North American Passenger Information System market ...
(Date:7/12/2014)... The "North American Interventional ... by Angioplasty Balloon (Plain/Old, Cutting), Stent ... Filter (Retrievable), Endovascular Stent Graft - ... the major market drivers, restraints, and ... , Browse 108 market data tables ...
Breaking Medicine News(10 mins):Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5
Other Contents